Paper Details
- Home
- Paper Details
Original Abstract of the Article :
Alirocumab (Praluent(®)) is a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) that is administered via subcutaneous injection every 2 weeks. Across ten phase III studies from the ODYSSEY clinical trial program in patients with heterozygous familial hypercholesterole...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1007/s40256-016-0166-3
データ提供：米国国立医学図書館（NLM）
Alirocumab: A New Hope for Hypercholesterolemia
Hypercholesterolemia, a condition characterized by high levels of cholesterol in the blood, is a major risk factor for heart disease. This review explores the potential of alirocumab, a new medication that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), in managing hypercholesterolemia. The authors, like skilled navigators charting a course through the complexities of cholesterol management, examine the clinical trials and data supporting the use of alirocumab. The review highlights the significant LDL-C lowering effects of alirocumab, both as monotherapy and in combination with statins, and its favorable safety profile. This research suggests that alirocumab could offer a valuable new option for individuals struggling to manage their cholesterol levels.
A Powerful Ally: Alirocumab Shows Promise in Cholesterol Management
The review's findings highlight the promising potential of alirocumab in managing hypercholesterolemia. This medication, like a skilled guide leading through a maze of cholesterol-related risks, offers a new approach to lowering LDL-C levels. The research suggests that alirocumab could be particularly beneficial for individuals with statin intolerance or inadequate LDL-C control despite statin therapy. This research underscores the importance of ongoing research and development in the field of cholesterol management, seeking to optimize treatment strategies and improve cardiovascular health.
Taking Charge: A Collaborative Approach to Cholesterol Management
This review underscores the importance of working closely with healthcare providers to manage hypercholesterolemia. Individuals with hypercholesterolemia should discuss their individual needs and preferences with their doctors to explore the most effective and safe treatment options, including the potential use of alirocumab. By staying informed and making informed decisions, individuals can actively participate in their healthcare and work toward achieving optimal cardiovascular health.
Dr.Camel's Conclusion
This review provides a comprehensive overview of alirocumab, a new medication for hypercholesterolemia. The review highlights the significant LDL-C lowering effects of alirocumab and its favorable safety profile. This research suggests that alirocumab could offer a valuable new option for individuals struggling to manage their cholesterol levels, particularly those with statin intolerance or inadequate LDL-C control despite statin therapy. As research continues to evolve, it is important to stay informed and discuss treatment options with healthcare providers to make informed decisions that best suit individual needs.
Date :
- Date Completed 2016-12-13
- Date Revised 2019-12-10
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.